AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in 2019 ...

In case you've faced some hurdles solving the clue, Nimble, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure time, and test your ...

The Heavy Bowgun is a powerhouse ranged weapon in Monster Hunter Wilds. While not nearly as nimble as the Light Bowgun or Bow, the Heavy Bowgun more than makes up for this with its powerful shots and ...

Nimble Project and Development is a local real estate-focused consulting business founded in 2022 by Nick Mazzocco. The company – which provides services in real estate strategy, development ...

"Nimble" is an adjective that describes someone or something that moves quickly and easily. It can also refer to a person's ability to think or react swiftly. Whether it's a dancer gliding ...

The Nimble Valet 3-in-1 charger adds a bit of upscale touch to your counter or nightstand while charging your daily gear at the fastest possible wireless speeds. We've tried our fair share of three-in ...

Just over a year ago, Colorado bike maker Canfield updated their small-batch steel hardtail, and now its back in much lighter titanium with the limited edition Ti Nimble 9. Canfield will weld just 100 ...

AbbVie, a global pharmaceutical company headquartered in North Chicago, is acquiring Madison-based Nimble Therapeutics for $200 million in cash, the companies said in a news release. AbbVie has around ...

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...

The deal includes a $200m cash payment from AbbVie at closing, subject to standard adjustments, alongside potential interim funding payments. Credit: © AbbVie Inc ...

AbbVie has agreed to acquire Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis, and a pipeline of ...